Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > $4.13
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jan 11, 2021 6:55pm
249 Views
Post# 32272569

RE:RE:RE:$4.13

RE:RE:RE:$4.13
ABCs123s wrote:

 

3burtc wrote: Investors see through the lies. Everyone and their dogs knows no delusion happened or will happen. Just strait up lies. The tiny delay is nothing compared to the billions, & billions that we be made. Glt the new guys & girls & welcome.

 

 


I mean dilution did happen post phase 2 results, but will dilution happen? That certainly is a possibility, they still need cash to cover phase 3, if theirs no partner/buyout. Theirs also a possibility of dilution with the amalgation of holdings into therapeutics.



Yes ... need to assume the company will be able to get the share price up and there will also be some dilution coming.  Hoping it to be a smaller dilution based on share price appreciation ... to keep the ship running.

Hey, if they can make it happen without dilution, great!  But probably not the best assumption to make at this time.  

IMO

----


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities